XNAS · Healthcare · Biotechnology
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.10 | -0.08 | +20.00% | $733,000 | ✅ Beat | +0.76% | -2.14% | — |
| 2026-05-12 | Q1 2026 | -0.11 | -0.12 | -9.09% | $0 | ❌ Miss | +3.29% | -16.38% | -23.00% |
| 2026-03-18 |
| Q4 2025 |
| -0.10 |
| 0.06 |
| +160.00% |
| $718,000 |
| ✅ Beat |
| +4.98% |
| +4.35% |
| +26.52% |
| 2025-11-12 | Q3 2025 | -0.15 | -0.17 | -13.33% | $132,000 | ❌ Miss | — | — | — |
| 2025-08-13 | Q2 2025 | -0.15 | -0.06 | +60.00% | $6.3M | ✅ Beat | -4.00% | +10.72% | +46.85% |
| 2025-03-11 | Q4 2024 | -0.17 | -0.13 | +23.53% | $76,000 | ✅ Beat | +2.04% | -6.04% | -47.96% |
| 2024-11-12 | Q3 2024 | -0.19 | -0.20 | -5.26% | $173,000 | ❌ Miss | -1.61% | -16.94% | -14.52% |
| 2024-08-13 | Q2 2024 | -0.22 | 0.12 | +154.55% | $169,000 | ✅ Beat | +14.98% | +28.64% | +26.37% |
Showing last 8 quarters.